Abstract
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells capable of differentiating
into adipocytes, osteoblasts and chondroblasts as well as secreting a vast array of
soluble mediators. This potentially makes MSCs important mediators of a variety of
therapeutic applications. They are actively under evaluation for immunomodulatory
purposes such as graft-versus-host disease and Crohn’s disease as well as regenerative
applications such as stroke and congestive heart failure. We report our method of
generating clinical-grade MSCs together with suggestions gathered from manufacturing
experience in our Good Manufacturing Practices facility.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method.Exp Hematol. 1974; 2: 83-92
- Multilineage potential of adult human mesenchymal stem cells.Science. 1999; 284: 143-147
- Mesenchymal stem cells.J Orthop Res. 1991; 9: 641-650
- Optimising human mesenchymal stem cell numbers for clinical application: a literature review.Stem Cells Int. 2012; 2012: 465259
- Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow.J Bone Miner Res. 1999; 14: 1115-1122
- Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.Int J Clin Exp Med. 2010; 3: 248-269
- Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow.Blood. 2001; 98: 2396-2402
- Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells.Bone Marrow Transplant. 2003; 32: 265-272
- Immunomodulatory properties of mesenchymal stromal cells.Blood. 2007; 110: 3499-3506
- Good manufacturing practices production of mesenchymal stem/stromal cells.Hum Gene Ther. 2011; 22: 19-26
- Translating research into clinical scale manufacturing of mesenchymal stromal cells.Stem Cells Int. 2011; 2010: 193519
- Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue.Stem Cells Dev. 2012; 21: 273-283
- Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM.Cytotherapy. 2006; 8: 437-444
- Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone.Proc Natl Acad Sci U S A. 2002; 99: 8932-8937
- Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta.Nat Med. 1999; 5: 309-313
- Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.Blood. 2003; 101: 3722-3729
- Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement.Cytotherapy. 2006; 8: 315-317
- The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering.Biomaterials. 2009; 30: 3415-3427
- Culture and use of mesenchymal stromal cells in phase I and II clinical trials.Stem Cells Int. 2010; 2010: 503593
- Immunosuppressive properties of mesenchymal stem cells.Stem Cell Rev. 2012; 8: 375-392
- Mesenchymal stem cells inhibit complement activation by secreting factor H.Stem Cells Dev. 2010; 19: 1803-1809
- Treatment of inflammatory diseases with mesenchymal stem cells.Inflamm Allergy Drug Targets. 2009; 8: 110-123
- Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation.Blood. 2010; 115: 1549-1553
- Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1.Haematologica. 2009; 94: 173-184
- Toward closed-system culture of blood origin endothelial cells.Transfusion. 2005; 45: 1201-1207
- Simultaneous expansion and harvest of hematopoietic stem cells and mesenchymal stem cells derived from umbilical cord blood.J Mater Sci Mater Med. 2010; 21: 3183-3193
- Reproducible growth and expansion of bone marrow derived mesenchymal stem cells (MSC), using a novel, automated and closed cell expansion system (CES) [abstract].Cytotherapy. 2008; 10
Article info
Publication history
Accepted:
September 14,
2012
Received:
September 13,
2012
Identification
Copyright
© 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
